Charles River Discovery Research Services Germany GmbH (formerly Oncotest GmbH), Am Flughafen 12-14, 79108, Freiburg, Germany.
4HF Biotec GmbH, Am Flughafen 14, Freiburg, 79108, Germany.
Commun Biol. 2020 Jul 9;3(1):367. doi: 10.1038/s42003-020-1077-z.
Patient-derived xenografts (PDX) have emerged as an important translational research tool for understanding tumor biology and enabling drug efficacy testing. They are established by transfer of patient tumor into immune compromised mice with the intent of using them as Avatars; operating under the assumption that they closely resemble patient tumors. In this study, we established 27 PDX from 100 resected gastric cancers and studied their fidelity in histological and molecular subtypes. We show that the established PDX preserved histology and molecular subtypes of parental tumors. However, in depth investigation of the entire cohort revealed that not all histological and molecular subtypes are established. Also, for the established PDX models, genetic changes are selected at early passages and rare subclones can emerge in PDX. This study highlights the importance of considering the molecular and evolutionary characteristics of PDX for a proper use of such models, particularly for Avatar trials.
患者来源异种移植(PDX)已经成为理解肿瘤生物学和进行药物疗效测试的重要转化研究工具。它们是通过将患者肿瘤转移到免疫缺陷小鼠中建立的,目的是将它们用作替身,假设它们与患者肿瘤非常相似。在这项研究中,我们从 100 例切除的胃癌中建立了 27 个 PDX,并研究了它们在组织学和分子亚型上的保真度。我们表明,建立的 PDX 保留了亲本肿瘤的组织学和分子亚型。然而,深入研究整个队列发现,并非所有的组织学和分子亚型都能建立。此外,对于建立的 PDX 模型,遗传变化在早期传代时被选择,并且在 PDX 中可能会出现罕见的亚克隆。这项研究强调了考虑 PDX 的分子和进化特征对于正确使用此类模型的重要性,特别是对于替身试验。